PL348634A1 - Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases - Google Patents

Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Info

Publication number
PL348634A1
PL348634A1 PL99348634A PL34863499A PL348634A1 PL 348634 A1 PL348634 A1 PL 348634A1 PL 99348634 A PL99348634 A PL 99348634A PL 34863499 A PL34863499 A PL 34863499A PL 348634 A1 PL348634 A1 PL 348634A1
Authority
PL
Poland
Prior art keywords
inhibitors
radiation
treatment
growth factor
factor receptor
Prior art date
Application number
PL99348634A
Other languages
English (en)
Inventor
Harlan W Waksal
Mansoor N Salech
Francisco Robert
Donald Jay Buchsbaum
Original Assignee
Imclone Systems Inc
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Uab Research Foundation filed Critical Imclone Systems Inc
Publication of PL348634A1 publication Critical patent/PL348634A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL99348634A 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases PL348634A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8561398P 1998-05-15 1998-05-15
US7961298A 1998-05-15 1998-05-15
US20613898A 1998-12-07 1998-12-07

Publications (1)

Publication Number Publication Date
PL348634A1 true PL348634A1 (en) 2002-06-03

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99348634A PL348634A1 (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Country Status (14)

Country Link
EP (1) EP1080113A4 (fr)
JP (1) JP2002515511A (fr)
KR (1) KR20010071271A (fr)
CN (1) CN1314917A (fr)
AU (1) AU4079999A (fr)
BR (1) BR9910511A (fr)
CA (1) CA2332331A1 (fr)
CZ (1) CZ20004224A3 (fr)
HK (1) HK1040720A1 (fr)
IL (1) IL139707A0 (fr)
MX (1) MXPA00011248A (fr)
PL (1) PL348634A1 (fr)
SK (1) SK17282000A3 (fr)
WO (1) WO1999060023A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (fr) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions et méthodes pour le traitement de tumeurs
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
WO2000074634A2 (fr) 1999-06-03 2000-12-14 Au Jessie L S Methodes et compositions permettant de moduler la proliferation et la mort cellulaire
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
JP2005526506A (ja) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的なヒト抗体及びその利用
DE60318561T2 (de) * 2002-04-02 2009-01-08 Nerviano Medical Sciences S.R.L., Nerviano Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005001053A2 (fr) 2003-06-09 2005-01-06 Samuel Waksal Procedes d'inhibition de tyrosine-kinases receptrices au moyen d'un antagoniste extracellulaire et d'un antagoniste intracellulaire
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
MXPA06001634A (es) 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
EP1694850B1 (fr) 2003-11-12 2011-06-29 Schering Corporation Systeme de plasmide pour l'expression multigenique
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1735348B1 (fr) 2004-03-19 2012-06-20 Imclone LLC Humain anticorps dirige contre le recepteur du facteur de croissance epidermique
AU2005249206A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an EGFR-inhibitor
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
ES2452115T3 (es) 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
WO2007035744A1 (fr) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Marqueurs biologiques predictifs d'une reaction anticancereuse aux inhibiteurs kinase du recepteur du facteur de croissance 1 analogue a l'insuline
EP3770174A1 (fr) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprenant des anticorps spécifiques aux espèces croisées et leurs utilisations
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2009001715A (es) 2006-08-21 2009-02-25 Hoffmann La Roche Terapia tumoral con un anticuerpo anti-vegf.
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
WO2009030368A1 (fr) 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Polythérapie avec des anticorps anti-cd20 de type i et de type ii
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
BRPI0917871A2 (pt) 2008-08-15 2017-06-20 Merrimack Pharmaceuticals Inc agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (fr) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
RU2504553C2 (ru) 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
EP2236139A1 (fr) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
JP2013501741A (ja) 2009-08-14 2013-01-17 ロシュ グリクアート アーゲー アフコシル化ｃｄ２０抗体とフルダラビン及び／又はミトキサントロンの併用療法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
KR101620661B1 (ko) 2010-04-27 2016-05-12 로슈 글리카트 아게 어푸코실화된 ＣＤ20 항체와 mTOR 억제제의 복합 요법
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2819436A1 (fr) 2010-12-16 2012-06-21 Roche Glycart Ag Therapie d'association d'un anticorps cd20 afucosyle avec un inhibiteur mdm2
WO2012106556A2 (fr) 2011-02-02 2012-08-09 Amgen Inc. Méthodes et compositions associées à l'inhibition d'igf-1r
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (fr) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Polythérapie du cancer du poumon non à petites cellules (nsclc)
MX2013011706A (es) 2011-04-07 2014-04-25 Amgen Inc Proteinas novedosas de enlace a antigeno.
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013071056A2 (fr) 2011-11-11 2013-05-16 Duke University Polythérapie médicamenteuse pour le traitement de tumeurs solides
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
CN104136464A (zh) * 2012-02-23 2014-11-05 U3制药有限公司 用于调节放射敏感性的her3抑制剂
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
KR102158467B1 (ko) 2012-09-07 2020-09-25 제넨테크, 인크. Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN113607945A (zh) 2015-07-07 2021-11-05 豪夫迈·罗氏有限公司 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
EP3405194A1 (fr) 2016-01-18 2018-11-28 Institut National de la Sante et de la Recherche Medicale (INSERM) Utilisation d'un inhibiteur temporaire de p53 à des fins de prévention ou de réduction des rechutes de cancer
CN109415441B (zh) 2016-05-24 2023-04-07 英斯梅德股份有限公司 抗体及其制备方法
EP3658584A1 (fr) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20
EP3658188A1 (fr) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Polythérapie faisant appel à un inhibiteur de bet et à un inhibiteur de bcl-2
TW201920282A (zh) * 2017-09-29 2019-06-01 中國大陸商上海藥明生物技術有限公司 抗egfr和pd-1的雙特異性抗體
WO2019201882A1 (fr) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur de bet et un inhibiteur du protéasome
WO2020234445A1 (fr) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2
WO2021155006A1 (fr) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
CA2222231A1 (fr) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
CA2332331A1 (fr) 1999-11-25
EP1080113A1 (fr) 2001-03-07
JP2002515511A (ja) 2002-05-28
BR9910511A (pt) 2001-11-20
CN1314917A (zh) 2001-09-26
EP1080113A4 (fr) 2002-04-17
CZ20004224A3 (cs) 2002-02-13
KR20010071271A (ko) 2001-07-28
AU4079999A (en) 1999-12-06
MXPA00011248A (es) 2004-09-06
HK1040720A1 (zh) 2002-06-21
IL139707A0 (en) 2002-02-10
SK17282000A3 (sk) 2002-04-04
WO1999060023A1 (fr) 1999-11-25

Similar Documents

Publication Publication Date Title
IL139707A0 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
HUP0201480A3 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
IL134013A0 (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
MD960217A (en) Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9903841D0 (en) Diagnosis and treatment of cancer
EP1073496A4 (fr) Catheter d'irradiation ameliore et procede d'utilisation
HUP0203035A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
EP1097165A4 (fr) Nouveaux inhibiteurs de l'angiogenese et de la croissance tumorale
AU6528800A (en) Methods and apparatuses for radiation treatment
IL126341A0 (en) Radiation delivery devices and methods of making same
AU3000297A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
AU6887698A (en) Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
HK1043113A1 (zh) 端粒酶抑制劑及其使用方法
DE60030164D1 (de) 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie
EP1054979A4 (fr) Compositions et procedes servant a sensibiliser et a inhiber la croissance de cellules cancereuses humaines
GB9811598D0 (en) Diagnosis and treatment of cancer
NO20021430L (no) Fremgangsmåte for terapeutisk forvaltning av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte ogegglederobstruksjon
AU4492000A (en) Determination of pacemaker wenckebach and adjustment of upper rate limit
EP1181374A4 (fr) Nouvelles kinases humaines et murines
EP1161451A4 (fr) Endokine alpha humain et methodes d'utilisation
IL153769A0 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
AU2002366230A1 (en) Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation
GB9812550D0 (en) Tumour therapy and imaging
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same